A South Carolina state senator has asserted that medical cannabis access is now legally established in the state, a development he attributes to the recent federal rescheduling of cannabis. State Senator Tom Davis (R), a proponent of medical cannabis legislation, stated that an existing state law was triggered by the federal action, effectively establishing a medical marijuana program in South Carolina. This perspective, reported by Marijuana Moment, suggests South Carolina could become the 41st U.S. state with a legally authorized medical cannabis program.
Legal Framework and State Obligations
Senator Davis’s declaration hinges on two specific state laws. The first mandates that “if a substance is added, deleted, or rescheduled as a controlled substance pursuant to federal law or regulation,” state officials must then reschedule the drug in the “appropriate schedule” under state law within 30 days. The second, the South Carolina Controlled Substances Therapeutic Research Act, enacted in 1980, established a program allowing certain patients to obtain medical cannabis “through whatever means” the state health commissioner “deems most appropriate consistent with federal law.”
Governor Henry McMaster’s (R) office confirmed to local media, as reported by Marijuana Moment, that South Carolina law will “require the State to mirror the new federal order” on cannabis rescheduling. The South Carolina Department of Public Health (DPH) has acknowledged awareness of the proposed rescheduling of medical marijuana from Schedule I to Schedule III under the Controlled Substances Act and is currently “assessing the impacts to DPH and the state of South Carolina.” Senator Davis indicated that Dr. Edward Simmer, as the DPH director, is statutorily obligated to provide medical cannabis to eligible patients under the existing law.
Political Opposition and Legislative History
Despite these legal interpretations, political opposition to broader medical cannabis reform persists. U.S. Representative Ralph Norman (R-SC), a gubernatorial candidate, expressed concerns about cannabis, referring to it as a “gateway drug.” He stated to Marijuana Moment that “medicinal cannabis never ends up like that, [and] always ends up opening it up to everybody.”
Senator Davis has repeatedly sponsored comprehensive medical cannabis legalization bills, which have twice passed the Senate but consistently stalled in the House of Representatives. He noted that the legislature has been “derelict in its duty” by failing to enact a measure that would establish safeguards, physician authorization, and pharmacist dispensing for medical cannabis, beyond the limited access potentially triggered by federal rescheduling.
Public Support and Future Outlook
Public opinion in South Carolina shows strong support for medical cannabis legalization. A 2024 poll found that 93 percent of Democrats, 74 percent of Republicans, and 84 percent of independents back the reform. However, House Speaker Murrell Smith (R) has previously tempered expectations, citing insufficient support within the GOP caucus to advance such reforms through his chamber.
Senator Davis has suggested that state officials could face litigation if they fail to take steps to provide legal medical cannabis access in line with current law. He anticipates potential legal actions by individuals seeking medicinal cannabis, aiming to compel the DPH to discharge its statutory duty. This situation underscores the ongoing tension between existing state statutes, federal regulatory changes, and legislative inaction regarding medical cannabis access in South Carolina.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
